W. Shi

发表

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.

Ying Cheng, Jian-hua Chang, Yunpeng Liu, 2020, The Lancet. Respiratory medicine.

Camrelizumab Plus Apatinib in Extensive-Stage Small-Cell Lung Cancer (PASSION): A Multicenter, Two-Stage, Phase 2 Trial.

Lifeng Wang, Yong Fang, Haihua Yang, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases.

G. Ku, K. Koyanagi, M. Slingerland, 2019, Journal of thoracic disease.

Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2021, Cancer Immunology, Immunotherapy.

A case of adult-onset Still’s disease accompanied with pulmonary tuberculosis successfully treated with colchicine

W. Shi, Shijia Rao, 2021, Advances in Dermatology and Allergology.

Dysfunction of apoptosis and autophagy correlates with local recurrence in esophageal squamous cell carcinoma after definitive chemoradiation

Hesheng Luo, Yongshun Chen, Jiamei Chen, 2021, Cancer cell international.

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma

Lei Zhang, Yongshun Chen, W. Shi, 2015, Oncotarget.

Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous non-small-cell lung cancer (CameL-sq): a phase 3 trial.

Ying Cheng, R. Guo, Yiping Zhang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities.

D H Leung, W. Shi, P. Pisters, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinoma

Yuehua Wu, Yongshun Chen, Jiamei Chen, 2022, Cancer medicine.

Circ_0011385 knockdown inhibits cell proliferation, migration and invasion, whereas promotes cell apoptosis by regulating miR-330-3p/MYO6 axis in colorectal cancer.

Zhenguo Shi, Yongshun Chen, Yuxin Cai, 2022, Biomedical journal.

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial

Ying Cheng, R. Guo, Sheng Hu, 2022, Molecular cancer.

ALG3 contributes to the malignancy of non-small cell lung cancer and is negatively regulated by MiR-98-5p.

Yongshun Chen, Chen Han, Jiamei Chen, 2019, Pathology, research and practice.

Clinical considerations for the management of cancer patients in the mitigation stage of the COVID-19 pandemic.

Qian Chen, Yongshun Chen, Chen Han, 2020, American journal of cancer research.

Preoperative chemotherapy for limited-stage small cell carcinoma of the esophagus.

Yongshun Chen, Jun Wang, Jiamei Chen, 2021, The Annals of thoracic surgery.

Surgery shows survival benefit in patients with primary intestinal diffuse large B‐cell lymphoma: A population‐based study

Shanshan Luo, Yu Hu, Yuanyuan Zhang, 2021, Cancer medicine.

MicroRNA-202-5p functions as a tumor suppressor in colorectal carcinoma by directly targeting SMARCC1.

Yongshun Chen, Jiamei Chen, W. Shi, 2018, Gene.

Radiotherapy plus camrelizumaband irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.

Yuehua Wu, Yongshun Chen, Shasha Ruan, 2023, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

P1.01-61 A Phase II Umbrella Study of Camrelizumab in Different PD-L1 Expression Cohorts in Pre-Treated Advanced/Metastatic Non-Small Cell Lung Cancer

Y. Wang, J. Yang, Y. Wu, 2019, Journal of Thoracic Oncology.

JCSE01.09 A Phase II Umbrella Study of Camrelizumab in Different PD-L1 Expression Cohorts in Pre-Treated Advanced/Metastatic Non-Small Cell Lung Cancer

Y. Wang, J. Yang, Y. Wu, 2019, Journal of Thoracic Oncology.

With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis.

Yi Wang, Yongshun Chen, Jun Wang, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases

Yongshun Chen, Jiamei Chen, W. Shi, 2018, Current Medical Science.

Down-regulation of HMGB 1 induces apoptosis and inhibits invasion and migration of MCF-7 breast cancer cells through targeting SMARCC 1

Yongshun Chen, H. Shi, W. Shi, 2017 .

FRESCO: A phase 2, randomized study of duvelisib plus rituximab vs R-CHOP in patients with relapsed/refractory follicular lymphoma who have progressed within 24 months of receiving an alkylator-based chemotherapy regimen.

J. Pearlberg, L. Brail, N. Fowler, 2016 .

Adebrelimab (SHR-1316) in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: an open-label, multicenter, phase 1b trial.

Yi-long Wu, W. Zhong, Lunxu Liu, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy of endoscopic therapy for T1b esophageal cancer and construction of prognosis prediction model: a retrospective cohort study

Yuehua Wu, Jingping Yuan, Yongshun Chen, 2023, International journal of surgery.

LBA5 A phase II study of neoadjuvant SHR-1701 with or without chemotherapy (chemo) followed by surgery or radiotherapy (RT) in stage III unresectable NSCLC (uNSCLC)

Y. Wu, Q. Pang, Y. Zhao, 2022, Immuno-Oncology and Technology.